Prognostic significance of midwall fibrosis in dilated cardiomyopathy
© Gulati et al; licensee BioMed Central Ltd. 2012
Published: 1 February 2012
Small studies with composite endpoints show that midwall fibrosis, identified by late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR), predicts short term adverse prognosis in dilated cardiomyopathy (DCM). We hypothesized that midwall fibrosis is an independent predictor of mortality over a long follow-up period.
Consecutive patients with DCM referred for CMR between 2002-2008 were prospectively enrolled. The diagnosis of DCM was made using clinical, CMR and coronary angiographic findings. Patients with ischemic heart disease, primary valvar disease and infiltrative CM were excluded. LGE-CMR at 1.5T (Siemens Sonata or Avanto, Germany) was performed in 2 phase-encoding directions. The presence of midwall LGE was determined by a specialist blinded to all outcome data. The primary endpoint was all-cause mortality. The secondary endpoint was a composite of cardiovascular (CV) mortality or cardiac transplantation.
Midwall fibrosis is a significant independent predictor of both all-cause mortality and CV mortality/transplantation in DCM. Detection of midwall fibrosis by LGE-CMR represents an important and novel marker for the risk stratification of DCM patients.
This work was supported by the NIHR Cardiovascular Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Dr Ankur Gulati receives salary support from CORDA.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.